On September 15, 2023, Hemanext ONE was granted marketing authorization for commercial distribution via the De Novo process by the U.S. Food & Drug Administration.
2023
On September 15, 2023, Hemanext ONE was granted marketing authorization for commercial distribution via the De Novo process by the U.S. Food & Drug Administration.